Cardiovascular diseases are among the most pressing issues facing the medical industry. With conditions like stroke or IHD (ischemic heart disease) contributing heavily to mortality and disability worldwide, cardiovascular devices and their significance in heart-related therapies are rapidly coming into the spotlight.
Several studies predict that the prevalence of cardiovascular disorders like coronary artery disease, heart failure, congenital heart disease, heart attacks, cardiomyopathy, and others are set to drive the cardiovascular devices market to USD 86.27 billion by 2028. Today, cardiovascular devices are gaining near-ubiquitous adoption as global populations grow older and become susceptibility to different cardiac ailments.
In this edition of MedTech Outlook, we present some of the most promising companies in the cardiovascular devices space. The issue features thought leadership articles from Michael Dale, Senior Vice President, Abbott [NYSE:ABT]. The edition also showcases innovative solutions from AQUAHeart that builds a simple, safe, and effective scalable heart ablation platform that can serve the underserved segments of the market. Aqua Heart is the only single shot high power short duration (HPSD) tool, which combines the best of RF and Balloon applications. Another prominent solution provider is Cardiac Revival Machines, which develops a family of implantable cardioverter defibrillators that offer life-long protection to patients at risk of sudden cardiac death (SCD), and a more cost-effective solution to the healthcare system.
Leafing through these pages will give you comprehensive insights into the innovative trends and latest developments in the cardio vascular devices landscape to help you make informed decisions in your cardiovascular device endeavor.




-(1)-1.jpg)










